Status:
ACTIVE_NOT_RECRUITING
Mild Water-filtered Infrared-A Whole-body Hyperthermia in Patients With Post-COVID Syndrome (HyPoCo)
Lead Sponsor:
Universität Duisburg-Essen
Collaborating Sponsors:
Bavarian State Ministry of Health and Care
Conditions:
Post-COVID Syndrome
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This study examines the efficacy of mild water-filtered whole-body hyperthermia during outpatient treatment in patients with post-COVID syndrome. The aim is to evaluate whether there can be an improve...
Detailed Description
A total of about 60 participants over 18 years of age are sought, who will be divided into two groups of equal size after inclusion in the study. All participants will receive the same amount of water...
Eligibility Criteria
Inclusion
- Patients aged between 18 and 75 years
- Confirmed diagnosis of post-COVID syndrome
- Fatigue: at least 51.5 points on the MFI-20 scale.
- Signed declaration of consent
Exclusion
- Participation in other clinical studies
- Contraindications for hyperthermia (severe cardiovascular diseases with/above NYHA II, active tumor diseases, acute infections, hyperthyroidism (not adjusted), pregnant and breastfeeding women, epilepsy, high-grade cardiac arrhythmia including atrial fibrillation, multiple sclerosis, major skin lesions, photosensitivity disease, acute exacerbated bronchial asthma/COPD \[Gold II to IV\])
- Pleuritic chest pain
- Hyperthyroidism
- Poorly controlled diabetes mellitus
- Condition after critical illness due to COVID-19
- Patients with active tumor disease, with pneumological, rheumatic, endocrine or neurological concomitant diseases (including dementia, epilepsy, multiple sclerosis), in particular neurological diseases associated with cognitive or sensory disorders
- Severe liver or kidney diseases (liver cirrhosis, post liver transplant, autoimmune hepatitis, dialysis patients, post kidney transplant, acute kidney failure, autoimmune nephropathy)
- Patients with chronic cannabis use (exception: CBD for myalgia), long-term use of WHO class III opioids (e.g. for myalgia/joint pain), long-term use of immunosuppressive medication (steroids, biologics, MTX, leflunomide, azathioprine)
- Patients with psychiatric disorders (bipolar disorder, psychosis, schizophrenia, personality disorder)
Key Trial Info
Start Date :
February 20 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06204458
Start Date
February 20 2024
End Date
May 31 2025
Last Update
April 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sozialstiftung Bamberg
Bamberg, Germany